Resultats globals: 18 registres trobats en 0.02 segons.
Articles, 15 registres trobats
Documents de recerca, 3 registres trobats
Articles 15 registres trobats  1 - 10següent  anar al registre:
1.
10 p, 917.8 KB Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins / Díez, José María (Grifols. Bioscience Research & Development) ; Romero, Carolina (Grifols. Bioscience Research & Development) ; Vergara-Alert, Júlia (Universitat Autònoma de Barcelona. Centre de Recerca en Sanitat Animal) ; Belló-Perez, Melissa (Laboratorio Coronavirus. Departamento de Biología Molecular y Celular) ; Rodon, Jordi (Universitat Autònoma de Barcelona. Centre de Recerca en Sanitat Animal) ; Honrubia, José Manuel (Laboratorio Coronavirus. Departamento de Biología Molecular y Celular) ; Segalés Coma, Joaquim (Universitat Autònoma de Barcelona. Departament de Sanitat i d'Anatomia Animals) ; Sola, Isabel (Laboratorio Coronavirus. Departamento de Biología Molecular y Celular) ; Enjuanes, Luis (Laboratorio Coronavirus. Departamento de Biología Molecular y Celular) ; Gajardo, Rodrigo (Grifols. Bioscience Research & Development)
Background: Cross-reactivity against human coronaviruses with Flebogamma ® DIF and Gamunex ® -C, two available intravenous immunoglobulins (IVIG), has been reported. In this study, these IVIG were tested for neutralization activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), SARS-CoV and Middle East respiratory syndrome CoV (MERS-CoV). [...]
2020 - 10.2217/imt-2020-0220
Immunotherapy, september 2020  
2.
10 p, 595.1 KB Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma / Wick, Antje (Heidelberg University Medical Center. Clinical Cooperation Unit Neuro-oncology, German Cancer Research Center) ; Desjardins, Annick (Duke University. The Preston Robert Tisch Brain Tumor Center at Duke) ; Suarez, Cristina (VHIO) ; Forsyth, Peter (H. Lee Moffitt Cancer Center and Research Institute) ; Gueorguieva, Ivelina (Eli Lilly and Company) ; Burkholder, Tiana (Eli Lilly and Company) ; Cleverly, Ann Louise (Eli Lilly and Company) ; Estrem, Shawn T. (Eli Lilly and Company) ; Wang, Shuaicheng (BioStat Solutions, Inc, Frederick, MD USA) ; Lahn, Michael M. (Eli Lilly and Company) ; Guba, Susan C. (Eli Lilly and Company) ; Capper, David (Department of Neuropathology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany) ; Rodon Ahnert, Jordi (VHIO) ; Universitat Autònoma de Barcelona
The online version of this article (10. 1007/s10637-020-00910-9) contains supplementary material, which is available to authorized users.
2020 - 10.1007/s10637-020-00910-9
Investigational New Drugs, Vol. 38 (march 2020) , p. 1570-1579  
3.
11 p, 2.3 MB Blocking transmission of Middle East respiratory syndrome coronavirus (MERS-CoV) in llamas by vaccination with a recombinant spike protein / Rodon, Jordi (Universitat Autònoma de Barcelona. Centre de Recerca en Sanitat Animal) ; Okba, Nisreen M. A. (Department of Viroscience, Erasmus Medical Centre) ; Te, Nigeer (Universitat Autònoma de Barcelona. Centre de Recerca en Sanitat Animal) ; van Dieren, Brenda (Utrecht University. Virology Division, Department of Infectious Diseases & Immunology. Faculty of Veterinary Medicine) ; Bosch, Berend-Jan (Utrecht University. Virology Division, Department of Infectious Diseases & Immunology. Faculty of Veterinary Medicine) ; Bensaid, Albert (Universitat Autònoma de Barcelona. Centre de Recerca en Sanitat Animal) ; Segalés Coma, Joaquim (Universitat Autònoma de Barcelona. Departament de Sanitat i d'Anatomia Animals) ; Haagmans, Bart L. (Department of Viroscience, Erasmus Medical Centre) ; Vergara-Alert, Júlia (Universitat Autònoma de Barcelona. Centre de Recerca en Sanitat Animal)
The ongoing Middle East respiratory syndrome coronavirus (MERS-CoV) outbreaks pose a worldwide public health threat. Blocking MERS-CoV zoonotic transmission from dromedary camels, the animal reservoir, could potentially reduce the number of primary human cases. [...]
2019 - 10.1080/22221751.2019.1685912
Emerging microbes & infections, Vol. 8 (november 2019) , p. 1593-1603  
4.
9 p, 297.7 KB New clinical trial designs in the era of precision medicine / Garralda, Elena (Universitat Autònoma de Barcelona) ; Dienstmann, Rodrigo (Universitat Autònoma de Barcelona) ; Piris-Giménez, Alejandro (Universitat Autònoma de Barcelona) ; Braña, Irene (Universitat Autònoma de Barcelona) ; Rodon Ahnert, Jordi (Universitat Autònoma de Barcelona) ; Tabernero, Josep (Universitat Autònoma de Barcelona) ; Universitat Autònoma de Barcelona ; VHIO Vall d'Hebron Institut d'Oncologia
Cancer treatment has made significant strides towards the promise of personalized medicine. Recent scientific advances have shown that there are numerous genetic deregulations that are common in multiple cancer types, raising the possibility of developing drugs targeting those deregulations irrespective of the tumour type. [...]
2019 - 10.1002/1878-0261.12465
Molecular Oncology, Vol. 13 (february 2019) , p. 549-557  
5.
11 p, 2.8 MB Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines : The Linx Registry / de Frutos, Fernando (Hospital Universitari de Bellvitge) ; Mirabet, Sonia (Institut d'Investigació Biomèdica Sant Pau) ; Ortega-Paz, Luis (Department of Cardiology, Hospital Clinic) ; Buera, Irene (Department of Cardiology, Hospital de Viladecans) ; Darnés, Sara (Department of Cardiology, Hospital de Figueres) ; Farré, Nuria (Institut Hospital del Mar d'Investigacions Mèdiques) ; Perez, Bernardo (Hospital de Granollers) ; Adeliño, Raquel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Bascompte, Ramón (Hospital Universitari Arnau de Vilanova) ; Pérez-Rodón, Jordi (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Aparicio, Xavier (Hospital de Mataró) ; Sutil-Vega, Mario (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Soto, Adriana (Hospital de Martorell) ; Faraudo, Mercedes (Hospital Moises Broggi) ; Cainzos-Achirica, Miguel (Hospital Universitari de Bellvitge) ; Manito, Nicolás (Hospital Universitari de Bellvitge) ; Universitat Autònoma de Barcelona
In May 2016, a new version of the European Society of Cardiology (ESC) Guidelines for the management of heart failure (HF) was released. The aim of this study was to describe the management of HF with reduced ejection fraction after the publication of ESC Guidelines. [...]
2020 - 10.1002/ehf2.12567
ESC Heart Failure, Vol. 7 (january 2020) , p. 25-35  
6.
8 p, 2.4 MB Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations / Tamborero, David (Institut Hospital del Mar d'Investigacions Mèdiques) ; Rubio-Perez, Carlota (Institut Hospital del Mar d'Investigacions Mèdiques) ; Deu-Pons, Jordi (Institut Hospital del Mar d'Investigacions Mèdiques) ; Schroeder, Michael P. (Charité-Universitätsmedizin (Germany)) ; Vivancos, Ana (Vall d'Hebron Institut d'Oncologia) ; Rovira, Ana (Institut d'Investigació Mèdica Hospital del Mar (IMIM)- CIBERONC) ; Tusquets, Ignasi (Institut Hospital del Mar d'Investigacions Mèdiques) ; Albanell, Joan (Institut Hospital del Mar d'Investigacions Mèdiques) ; Rodón Ahnert, Jordi (Vall d'Hebron Institut d'Oncologia) ; Taberneroo, J (Vall d'Hebron Institut d'Oncologia) ; de Torres, Carmen (Institut de Recerca Pediàtrica. Hospital Sant Joan de Déu) ; Dienstmann, Rodrigo (Vall d'Hebron Institut d'Oncologia) ; Gonzalez-Perez, Abel (Institut Hospital del Mar d'Investigacions Mèdiques) ; Lopez-Bigas, Nuria (Institució Catalana de Recerca i Estudis Avançats (ICREA)) ; Universitat Autònoma de Barcelona
While tumor genome sequencing has become widely available in clinical and research settings, the interpretation of tumor somatic variants remains an important bottleneck. Here we present the Cancer Genome Interpreter, a versatile platform that automates the interpretation of newly sequenced cancer genomes, annotating the potential of alterations detected in tumors to act as drivers and their possible effect on treatment response. [...]
2018 - 10.1186/s13073-018-0531-8
Genome Medicine, Vol. 10 (March 2018) , art. 25  
7.
10 p, 506.2 KB Analysis of mutant allele fractions in driver genes in colorectal cancer - biological and clinical insights / Dienstmann, Rodrigo (Vall d'Hebron Institut d'Oncologia) ; Élez Fernández, María Elena (Hospital Universitari Vall d'Hebron) ; Argilés Martínez, Guillem (Vall d'Hebron Institut d'Oncologia) ; Matos, Ignacio (Vall d'Hebron Institut d'Oncologia) ; Sanz García, Enrique (Vall d'Hebron Institut d'Oncologia) ; Ortiz, Carolina (Vall d'Hebron Institut d'Oncologia) ; Macarulla Mercadé, Teresa (Vall d'Hebron Institut d'Oncologia) ; Capdevila, Jaume (Vall d'Hebron Institut d'Oncologia) ; Alsina Maqueda, Maria (Vall d'Hebron Institut d'Oncologia) ; Sauri, Tamara (Vall d'Hebron Institut d'Oncologia) ; Verdaguer, Helena (Vall d'Hebron Institut d'Oncologia) ; Vilaró, Marta (Vall d'Hebron Institut d'Oncologia) ; Ruiz-Pace, Fiorella (Vall d'Hebron Institut d'Oncologia) ; Viaplana, Cristina (Vall d'Hebron Institut d'Oncologia) ; García Rodríguez, Ariadna (Vall d'Hebron Institut d'Oncologia) ; Landolfi, Stefania (Universitat Autònoma de Barcelona) ; Palmer, Hector G. (Vall d'Hebron Institut d'Oncologia) ; Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ; Rodón Ahnert, Jordi (Vall d'Hebron Institut d'Oncologia) ; Vivancos, Ana (Vall d'Hebron Institut d'Oncologia) ; Taberneroo, J (Vall d'Hebron Institut d'Oncologia)
Sequencing of tumors is now routine and guides personalized cancer therapy. Mutant allele fractions (s, or the 'mutation dose') of a driver gene may reveal the genomic structure of tumors and influence response to targeted therapies. [...]
2017 - 10.1002/1878-0261.12099
Molecular Oncology, Vol. 11, Issue 9 (September 2017) , p. 1263-1272  
8.
5 p, 5.1 MB Life-threatening and life-saving inappropriate implantable cardioverter defibrillator shocks / Pérez Rodon, Jordi (Universitat Autònoma de Barcelona) ; Doiny, David (Universitat Autònoma de Barcelona) ; Miranda, Berta (Universitat Autònoma de Barcelona) ; Rivas Gándara, Nuria (Universitat Autònoma de Barcelona) ; Roca Luque, Ivo (Universitat Autònoma de Barcelona) ; Francisco Pascual, Jaume (Universitat Autònoma de Barcelona) ; Lidón, Rosa Maria (Universitat Autònoma de Barcelona) ; García Dorado, David (Universitat Autònoma de Barcelona) ; Moya Mitjans, Àngel (Universitat Autònoma de Barcelona)
An implantable cardioverter defibrillator (ICD) lead dislodgement into the right atrium is a dangerous situation, particularly in patients in atrial fibrillation because atrial fibrillation can be sensed as ventricular fibrillation and true ventricular fibrillation induced with an inappropriate shock. [...]
2017 - 10.1002/ccr3.893
Clinical Case Reports, Vol. 5, Issue 4 (April 2017) , p. 521-525  
9.
8 p, 500.8 KB Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer / Gueorguieva, Ivelina (Eli Lilly and Company (United Kingdom)) ; Cleverly, Ann (Eli Lilly and Company (United Kingdom)) ; Desaiah, Durisala (Eli Lilly and Company (USA)) ; Azaro, Analía (Hospital Universitari Vall d'Hebron) ; Seoane Suárez, Joan (Vall d'Hebron Institut d'Oncologia) ; Braña, Irene (Hospital Universitari Vall d'Hebron) ; Sicart, Elisabet (Hospital Universitari Vall d'Hebron) ; Miles, Colin (Eli Lilly and Company (United Kingdom)) ; Lahn, Michael M (Eli Lilly and Company (USA)) ; Mitchell, Malcolm I (Eli Lilly and Company (USA)) ; Rodón Ahnert, Jordi (Vall d'Hebron Institut d'Oncologia) ; Universitat Autònoma de Barcelona
Galunisertib (LY2157299 monohydrate), an inhibitor of the transforming growth factor β (TGFβ) pathway, is currently under investigation in several clinical trials involving multiple tumor types. The primary objective of this study was to assess relative bioavailability of two new galunisertib formulations developed using the roller compaction (RC) dry-milled (RCD) and RC slurry-milled (RCS) processes, compared with the existing formulation developed using the high-sheer wet granulation (HSWG) process. [...]
2016 - 10.7573/dic.212303
Drugs in Context, Vol. 5 (December 2016) , art. 201303  
10.
13 p, 501.3 KB A phase I pharmacokinetic and safety study of cabazitaxel in adult cancer patients with normal and impaired renal function / Azaro, Analía (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ; Rodón, Jordi (Hospital Universitari Vall d'Hebron) ; Machiels, Jean-Pascal (Department of Medical Oncology, Institut Roi Albert II, Cliniques Universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale (Pole MIRO), Université Catholique de Louvain, Brussels, Belgium) ; Rottey, Sylvie (Department of Medical Oncology, University Hospital of Ghent and Heymans Institute of Pharmacology, Ghent University, Ghent, Belgium) ; Damian, Silvia (Department of Medical Oncology, Fondazione IRCCS National Cancer Institute of Milan, Milan, Italy) ; Baird, Richard (Early Phase Clinical Trials Team, Department of Oncology, University of Cambridge, Cambridge, UK) ; Garcia-Corbacho, Javier (Early Phase Clinical Trials Team, Department of Oncology, University of Cambridge, Cambridge, UK) ; Mathijssen, Ron H. J. (Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands) ; Clot, Pierre-François (Sanofi, Chilly-Mazarin, France) ; Wack, Claudine (Sanofi, Chilly-Mazarin, France) ; Shen, Liji (Sanofi, Bridgewater, NJ USA) ; de Jonge, Maja J. A. (Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands)
Limited data are available on cabazitaxel pharmacokinetics in patients with renal impairment. This open-label, multicenter study assessed cabazitaxel in patients with advanced solid tumors and normal or impaired renal function. [...]
2016 - 10.1007/s00280-016-3175-7
Cancer Chemotherapy and Pharmacology, Vol. 78 (october 2016) , p. 1185-1197  

Articles : 15 registres trobats   1 - 10següent  anar al registre:
Documents de recerca 3 registres trobats  
1.
7.5 MB ER+ metastatic breast cancer targeted therapy: biomarkers of response and mechanisms of resistance to PI3K and FGFR inhibitors / Sánchez Guixé, Mònica, ; Bayascas Ramírez, José Ramón, dir. ; Serra Elizalde, Violeta, dir. ; Graupera i Garcia-Milà, Mariona, dir. ; Rodon Ahrnet, Jordi, dir. ; Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular
La teràpia endocrina és un dels majors avenços en el tractament de càncer de mama (CM) dels últims 30 anys. Tot i això, les pacients acaben recaient degut a mecanismes de resistència, com ara les alteracions de la via de PI3K/mTOR i de FGFR. [...]
Endocrine therapy has been one of the major advances in the treatment of breast cancer (BC) for the past 30 years. However, patients eventually relapse due to mechanisms of resistance. These involve several pathways related to proliferation and growth, including the PI3K/mTOR and FGFR pathways. [...]

[Barcelona] : Universitat Autònoma de Barcelona, 2020.  
2.
201 p, 1.8 MB Optimización del tratamiento farmacológico en pacientes con disfunción sistólica severa del ventrículo izquierdo en una unidad de insuficiencia cardiaca: implicaciones en la indicación de un desfibrilador automático implantable en prevención primaria y factores predictores de ausencia de remodelado reverso del ventrículo izquierdo / Pérez Rodon, Jordi ; Galve Basilio, Enrique, dir. ; Moya Mitjans, Àngel, dir. ; García Dorado, D., dir. ; Universitat Autònoma de Barcelona. Departament de Medicina
[Barcelona] : Universitat Autònoma de Barcelona, 2016  
3.
200 p, 4.9 MB Biomarcadores farmacodinámicos y predictivos de respuesta en la toma de decisiones en ensayos clínicos Fase I de terapias dirigidas contra el cáncer / Rodón Ahnert, Jordi ; Tabernero Cartula, Josep, dir. ; Bosch Gil, Josep Angel ; Universitat Autònoma de Barcelona. Departament de Medicina
Este trabajo se centra en el papel de los biomarcadores en el desarrollo temprano de fármacos en Oncología, e introduce un concepto nuevo como es la implementación precoz de marcadores predictivos de respuesta en estudios fase I como estrategia para acelerar la toma de decisiones en el desarrollo de un fármaco experimental. [...]
This work focuses on the role of biomarkers in the early development of drugs in oncology, and introduces a new concept such as the early implementation of predictive markers of response in phase I studies as a strategy to accelerate decision-making in the development of an experimental drug. [...]

[Barcelona] : Universitat Autònoma de Barcelona, 2015  

Vegeu també: autors amb noms similars
2 Rodon, J.
1 Rodon, Jaume
11 Rodon, Jordi
2 Rodón, J.
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.